News >

Mirvetuximab Soravtansine Shows Benefit in Folate Receptor Alpha+ Ovarian Cancer

Gina Columbus @ginacolumbusonc
Published: Friday, May 03, 2019

Mark Enyedy

Mark Enyedy

The antibody-drug conjugate mirvetuximab soravtansine demonstrated a favorable benefit-risk profile in a prespecified subset of patients with folate receptor alpha (FRα)–positive ovarian cancer, following a comprehensive analysis of the phase III FORWARD I trial, according to ImmunoGen, the manufacturer of the agent.1

The news follows the company’s March 2019 announcement that mirvetuximab soravtansine missed the study’s primary endpoint of progression-free survival (PFS) compared with chemotherapy in patients with FRα–positive, platinum-resistant ovarian cancer and in an overall patient population.2 Although PFS was longer with mirvetuximab soravtansine in the prespecified high FRα–positive subgroup (HR, 0.69; P = .049), it was not enough to reach statistical significance as per a prespecified statistical analysis plan.

In the overall study population, no significant difference in PFS was observed (HR, 0.98; P = .897).

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: ASCO Direct™ Highlights – 2019 Official Annual Meeting ReviewAug 30, 20201.5
Community Practice Connections™: Advances in Ovarian Cancer: Evolving Applications for PARP Inhibitors, Immunotherapy & Beyond!Aug 30, 20201.5
Publication Bottom Border
Border Publication